Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683681 | 0.84 | PTGS1 (0.50) | PTGS1PTGS2S1PR4HPGDSMN1; SMN2 | |
| SCHEMBL3689267 | 0.82 | PTGER1 (0.36) | EPRS1PTGER1RXFP1HTT | |
| SCHEMBL1583276 | 0.80 | EPRS1 (0.35) | EPRS1LMNASMN1; SMN2PTGER1RXFP1 | |
| SCHEMBL3688527 | 0.78 | PTGS1 (0.41) | PTGS1PTGS2KMT2A | |
| SCHEMBL13229138 | 0.78 | EPRS1 (0.34) | EPRS1PTGER1RXFP1 | |
| SCHEMBL3701973 | 0.77 | LMNA (0.45) | LMNAHPGDRXFP1KMT2AMEN1 | |
| SCHEMBL3690213 | 0.72 | NOTUM (0.44) | SMN1; SMN2KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL1583159 | 0.71 | NOTUM (0.40) | SMN1; SMN2RXFP1KMT2AMEN1MAPT | |
| SCHEMBL3689295 | 0.70 | MEN1 (0.42) | S1PR4SMN1; SMN2RXFP1KMT2AMEN1 | |
| SCHEMBL1583997 | 0.69 | PTGER1 (0.33) | EPRS1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | PTGS1 757/4885PTGS2 1003/4885S1PR4 4080/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | PTGS1 757/4885PTGS2 1003/4885S1PR4 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.